Your browser is no longer supported. Please, upgrade your browser.
Settings
LOGC LogicBio Therapeutics, Inc. daily Stock Chart
LOGC [NASD]
LogicBio Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.49 Insider Own0.30% Shs Outstand23.88M Perf Week-0.13%
Market Cap182.68M Forward P/E- EPS next Y-1.84 Insider Trans0.00% Shs Float16.17M Perf Month-19.05%
Income-35.70M PEG- EPS next Q-0.49 Inst Own71.60% Short Float1.43% Perf Quarter-34.05%
Sales- P/S- EPS this Y-985.30% Inst Trans0.63% Short Ratio5.26 Perf Half Y-45.08%
Book/sh2.35 P/B3.26 EPS next Y-4.00% ROA-48.50% Target Price22.00 Perf Year-21.13%
Cash/sh2.65 P/C2.89 EPS next 5Y- ROE-53.00% 52W Range6.34 - 20.07 Perf YTD-26.44%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-61.89% Beta-
Dividend %- Quick Ratio15.70 Sales past 5Y- Gross Margin- 52W Low20.66% ATR0.46
Employees23 Current Ratio15.70 Sales Q/Q- Oper. Margin- RSI (14)28.66 Volatility6.59% 6.31%
OptionableNo Debt/Eq0.18 EPS Q/Q-113.50% Profit Margin- Rel Volume1.34 Prev Close7.97
ShortableYes LT Debt/Eq0.18 EarningsDec 02 BMO Payout- Avg Volume44.02K Price7.65
Recom1.60 SMA20-8.14% SMA50-17.98% SMA200-30.99% Volume59,154 Change-4.02%
May-01-19Initiated ROTH Capital Buy $26
Nov-14-19 06:57AM  We're Hopeful That LogicBio Therapeutics (NASDAQ:LOGC) Will Use Its Cash Wisely Simply Wall St.
Nov-12-19 08:00AM  LogicBio Reports Third Quarter 2019 Financial Results and Provides Business Updates GlobeNewswire
Nov-08-19 10:47AM  Is LogicBio Therapeutics, Inc. (LOGC) A Good Stock To Buy? Insider Monkey -5.07%
Nov-07-19 08:00AM  LogicBio Therapeutics to Present at November Conferences GlobeNewswire
Oct-16-19 08:00AM  LogicBio Therapeutics to Present New Data on Next Generation Capsid Development Program and GeneRide Platform Program at the European Society of Gene and Cell Therapy 27th Annual Congress GlobeNewswire
Oct-09-19 04:15PM  Horizon Technology Finance Provides Third Quarter 2019 Portfolio Update PR Newswire
Sep-26-19 08:00AM  LogicBio Therapeutics to Present at October Conferences GlobeNewswire -5.28%
Aug-13-19 08:00AM  LogicBio Reports Second Quarter 2019 Financial Results and Provides Business Updates GlobeNewswire +7.95%
May-31-19 10:58AM  Opening Bell, May 31, 2019 CNBC Videos
May-30-19 08:00AM  LogicBio to Present at the Jefferies 2019 Healthcare Conference GlobeNewswire
May-14-19 08:07AM  LogicBio Therapeutics: 1Q Earnings Snapshot Associated Press
08:00AM  LogicBio Reports First Quarter 2019 Financial Results and Provides Business Updates GlobeNewswire
May-13-19 06:47PM  Kamada (KMDA) to Report Q1 Earnings: What's in the Cards? Zacks
04:24PM  Dr. Reddy's (RDY) to Report Q4 Earnings: What's in Store? Zacks
Apr-29-19 08:00AM  LogicBio Therapeutics Receives FDA Orphan Drug Designation for LB-001 for the Treatment of Methylmalonic Acidemia GlobeNewswire +9.17%
Apr-22-19 08:00AM  LogicBio Therapeutics Expands Leadership Team and Bolsters Capabilities to Support GeneRide Platform Development and Advancement of Lead Program into Clinic GlobeNewswire
Apr-01-19 08:19AM  LogicBio Therapeutics: 4Q Earnings Snapshot Associated Press
08:00AM  LogicBio Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Updates GlobeNewswire
Mar-07-19 01:55PM  LogicBio planning first trial of gene editing treatment for children American City Business Journals +5.26%
Feb-25-19 07:00AM  LogicBio Therapeutics to Present at Upcoming March Conferences GlobeNewswire
Feb-22-19 07:00AM  LogicBio Therapeutics Appoints Kenneth Huttner, M.D., Ph.D., as Senior Vice President, Head of Clinical Development GlobeNewswire
Dec-06-18 08:00AM  LogicBio Therapeutics Appoints Richard Moscicki, M.D., and Michael Wyzga to Board of Directors GlobeNewswire
Dec-03-18 08:00AM  LogicBio Reports Third Quarter 2018 Financial Results GlobeNewswire -7.70%
Nov-15-18 06:00AM  LogicBio Announces Partnership with Childrens Medical Research Institute to Develop Next Generation Viral Vectors GlobeNewswire -6.19%
Nov-13-18 08:00AM  LogicBio to Present at the Jefferies 2018 London Healthcare Conference GlobeNewswire
Nov-11-18 09:10AM  The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs Benzinga
Oct-24-18 02:00AM  Arix Bioscience plc - LogicBio Announces Closing of Initial Public Offering PR Newswire -21.98%
Oct-23-18 04:05PM  LogicBio Therapeutics Announces Closing of Initial Public Offering GlobeNewswire -8.60%
Oct-22-18 04:00PM  Chardan Serves as Lead Manager for LogicBio Therapeutics PR Newswire
Oct-19-18 06:42AM  LogicBio's IPO: What You Need To Know Benzinga
Oct-15-18 01:10PM  IPO Outlook For The Week: E-Scooters, Drugs And Hotel Service Benzinga
LogicBio Therapeutics, Inc., a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect. Its lead product candidate is LB-001 for the treatment of Methylmalonic Acidemia, a life-threatening disease that presents at birth. The company has a partnership with Children's Medical Research Institute to develop new viral vectors. LogicBio Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.